Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:04 2022-10-07 pm EDT
326.66 USD   -1.89%
11:03aUBS Adjusts Eli Lilly and Company Price Target to $381 From $363, Maintains Buy Rating
MT
10/06Global markets live: General Electric, Twitter, Ford, Eli Lilly, Peloton...
MS
10/06Conflicting signals
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly, Innovent's Tyvyt Gets Approval for Treatment of Esophageal Cancer in China

06/21/2022 | 04:20am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -1.89% 326.66 Delayed Quote.20.11%
INNOVENT BIOLOGICS, INC. -3.17% 24.4 Delayed Quote.-49.43%
All news about ELI LILLY AND COMPANY
11:03aUBS Adjusts Eli Lilly and Company Price Target to $381 From $363, Maintains Buy Rating
MT
10/06Global markets live: General Electric, Twitter, Ford, Eli Lilly, Pel..
MS
10/06Conflicting signals
MS
10/06ETF Preview: ETFs, Futures Retreat Pre-Bell After Jobless Claims Report
MT
10/06Eli Lilly Starts Rolling Submission for Obesity Treatment; US FDA Grants Fast Track Des..
MT
10/06Eli Lilly gets FDA's speedy review for obesity drug
RE
10/06Eli Lilly Says FDA Grants Fast-Track Designation for Obesity Therapy
MT
10/06Eli Lilly to start rolling submission for obesity drug this year
RE
10/06Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adu..
PR
10/06Lilly Receives U.S. FDA Fast Track Designation for Tirzepatide for the Treatment of Adu..
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 28 831 M - -
Net income 2022 6 377 M - -
Net Debt 2022 10 717 M - -
P/E ratio 2022 48,3x
Yield 2022 1,15%
Capitalization 316 B 316 B -
EV / Sales 2022 11,3x
EV / Sales 2023 10,7x
Nbr of Employees 35 000
Free-Float 99,7%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 332,95 $
Average target price 338,62 $
Spread / Average Target 1,70%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY20.11%316 361
JOHNSON & JOHNSON-5.35%425 691
ROCHE HOLDING AG-14.13%271 357
ABBVIE INC.3.61%248 046
PFIZER, INC.-25.28%241 836
NOVO NORDISK A/S8.79%239 090